Technology | December 22, 2014

AliveCor Launches Third Generation Heart Monitor Smartphone App System

New compact medical grade mobile ECG device is 50-percent thinner, 40-percent lighter

AliveCor Heart Monitor, third generation, ECG, atrial fibrillation, AF

December 22, 2014 — AliveCor Inc. announced the launch of its third-generation AliveCor Heart Monitor. Now users have the ability to identify and manage heart conditions with a U.S. Food and Drug Administration (FDA)-cleared electrocardiogram (ECG) monitor, anywhere and at anytime. The third-generation device is now 50-percent thinner and 40-percent lighter and was designed from first-hand customer feedback and in collaboration with global design firm IDEO.

Atrial fibrillation (AF) continues to be the most common heart rhythm disturbance, affecting more than 140 million people worldwide. AliveCor is focused on helping those with diagnosed and undiagnosed heart conditions, by providing patients and caregivers a tool to detect and manage heart conditions.

Users of the AliveCor Heart Monitor are recording 130,000 ECGs per month and actively tracking over 10,000 symptoms, medications and activities that may be affecting their health. In the two months since the AF Detector algorithm was launched, AliveCor has detected more than 20,000 incidents of AF in more than 30 percent of users recording ECGs.

Detecting AF is the first step to initiating a treatment plan to reduce stroke risk, as people with AF are five times more likely to suffer a stroke than those without the condition. Additionally, users continue to engage with the product over time: 70 percent are regularly using the device after six months.

“I used to get frustrated when I would experience what I thought was an AF episode but couldn’t get to the doctor’s office fast enough to confirm my instincts,” said Terry Reilly, AliveCor patient since 2012. “With the AliveCor Heart Monitor, I am relieved to have an easy-to-use tool at my fingertips that can instantly detect my AF episodes when they happen.”

“The AliveCor Heart Monitor leads to results that I can use to manage my patients remotely, a trend that is here to stay," said Jeffrey Olgin, M.D., chief, division of cardiology co-director, Heart and Vascular Center at the University of California San Francisco. “Seeing my patients’ ECG results in real-time is the next best thing to having them in my office when the event takes place.” 

“Big data and personalized medicine are revolutionizing the delivery of care and have the potential to disrupt the way we think about healthcare. We are excited to be on the forefront of helping patients manage their cardiac health,” said Euan Thomson, president and chief executive officer at AliveCor. “The newest generation of the Heart Monitor confirms AliveCor’s ongoing commitment to help stop the unnecessary loss of life and healthcare costs driven by undiagnosed and under-managed heart arrhythmias that lead to potentially life-threatening conditions like strokes.”

For more information: www.alivecor.com

Related Content

Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 24, 2018
Atrial fibrillation patients who are diagnosed with carotid artery disease face higher risks for developing dementia,...
Botulinum Toxin (botox) Injection in CABG Patients Reduces AFib After Cardiac Surgery. #HRS2018

Figure 1: At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group

News | Atrial Fibrillation | May 18, 2018
 
Atrial fibrillation ablation using the Abbott Ensite electro mapping system. CABANA Trial Confirms Ablation Equal To or Superior to Drug Therapy. #HRS2018

Atrial fibrillation ablation using the Abbott Ensite electro mapping system.

Feature | Atrial Fibrillation | May 17, 2018
May 16, 2018 – The first results of the randomized, multicenter, long-term, international...
Link Found Between Post-Traumatic Stress, Increased Risk of AFib. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and ne
Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricul
First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

News | Atrial Fibrillation | May 15, 2018
May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception a
New Combined Risk Score More Effectively Predicts Stroke Risk in AFib Patients

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 11, 2018
A new study finds that integrating two separate clinical risk score models more accurately helps clinicians assess the...
Depression Linked to Increased Atrial Fibrillation Risk
News | Atrial Fibrillation | March 27, 2018
March 27, 2018 — Depression may increase the risk for...
Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Overlay Init